for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Getinge AB

GETIb.ST

Latest Trade

168.40SEK

Change

-0.30(-0.18%)

Volume

548,594

Today's Range

165.40

 - 

169.00

52 Week Range

126.70

 - 

204.80

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Getinge Q1 Adjusted EBITA Up At SEK 661 Mln

April 22 (Reuters) - Getinge AB <GETIb.ST>::GETINGE INTERIM REPORT FOR JANUARY-MARCH 2020: INTENSE EFFORTS TO HELP HOSPITALS IN THE COVID-19 PANDEMIC.QUARTER WAS DOMINATED BY COVID-19 PANDEMIC AND HUGE NEED FOR ADVANCED VENTILATORS AND ECMO THERAPY AT INTENSIVE CARE UNITS AROUND WORLD.Q1 ADJUSTED EBITA AT SEK 661 MILLION VERSUS SEK 369 MILLION YEAR AGO.GETINGE ANNOUNCED AT START OF APRIL AN INCREASED PRODUCTION CAPACITY OF VENTILATORS BY 160% COMPARED WITH 2019.GETINGE EXPECTS HIGH DELIVERY RATE TO CONTINUE INTO 2021 AND SUBSEQUENTLY GRADUALLY RETURN TO PAST LEVELS.Q1 NET SALES AT SEK 6,033 MILLION VERSUS SEK 5,548 MILLION YEAR AGO.GETINGE HAS MADE CERTAIN COST ADJUSTMENTS AND HAVE CONTINGENCY IN PLACE TO FURTHER ADJUST COSTS IF NECESSARY..

Getinge Issues COVID-19 Commercial Paper Of SEK 1 Bln

April 17 (Reuters) - Getinge AB <GETIb.ST>::ISSUES COVID-19 COMMERCIAL PAPER OF SEK 1 BILLION.DUE DATE OCT 21, 2020.

Getinge Q1 Adjusted EBITA Up At About SEK 660 Mln

April 9 (Reuters) - Getinge AB <GETIb.ST>::TO POST HIGHER THAN EXPECTED ORDER GROWTH AND EARNINGS FOR Q1 2020 AND WITHDRAWS OUTLOOK FOR 2020.GETINGE'S MULTIPLE EFFORTS TO SUPPORT HOSPITALS AND PATIENTS AFFECTED BY COVID-19 HAS CONTRIBUTED TO ORDER INTAKE FOR Q1 2020 BEING HIGHER THAN EXPECTED BY MARKET..ORDER INTAKE FOR Q1 2020 INCREASED BY 47.2% ORGANICALLY COMPARED TO Q1 2019 AND AMOUNTED TO APPROXIMATELY SEK 9,450 M.SIGNIFICANTLY INCREASED ORDER INTAKE IN BUSINESS AREA ACUTE CARE THERAPIES, AMOUNTING TO 96.4% COMPARED TO Q1 2019..ADJUSTED EBITA, WHICH WAS SUPPORTED BY INCREASED VOLUMES, OPERATIONAL LEVERAGE AND POSITIVE CURRENCY EFFECTS, INCREASED TO APPROXIMATELY SEK 660 M COMPARED TO SEK 369 M Q1 2019.INCREASE IS ATTRIBUTABLE TO CRITICAL CARE AND CARDIOPULMONARY, WHICH ARE PRODUCT CATEGORIES WHERE GETINGE IS A GLOBAL LEADER..DUE TO HIGH LEVELS OF UNCERTAINTY RELATED TO COVID-19 OUTBREAK IMPACT GETINGE WITHDRAWS OUTLOOK FOR ORGANIC NET SALES GROWTH FOR 2020.ON CORONAVIRUS: CONSEQUENCE FROM COVID-19, GETINGE WITHDRAWS OUTLOOK FOR ORGANIC NET SALES GROWTH IN 2020.

Getinge Enters Partnership With WaterAid

April 3 (Reuters) - Getinge AB <GETIb.ST>::GETINGE AND WATERAID PARTNER UP TO STRENGTHEN ACCESS TO CLEAN WATER, SANITATION AND HYGIENE AT HEALTH CARE FACILITIES AROUND THE WORLD.ANNOUNCES A PARTNERSHIP WITH INTERNATIONAL ORGANIZATION WATERAID..

Getinge Increases Production Capacity Of Ventilators With 60% To Support The Needs Of Global Intensive Care Units

March 17 (Reuters) - Getinge AB <GETIb.ST>::GETINGE INCREASES PRODUCTION CAPACITY OF VENTILATORS WITH 60% TO SUPPORT THE NEEDS OF GLOBAL INTENSIVE CARE UNITS.HAS SINCE OUTBREAK OF COVID-19 PANDEMIC SEEN AN INCREASED GLOBAL DEMAND FOR VENTILATORS, EXTRA CORPOREAL LIFE SUPPORT (ECLS) EQUIPMENT AND ADVANCED MONITORING FOR INTENSIVE CARE UNITS.TO MEET GLOBAL DEMAND GETINGE WILL TEMPORARY INCREASE ITS PRODUCTION OF VENTILATORS BY 60% IN 2020 COMPARED TO 2019 AT ITS PRODUCTION FACILITY IN SOLNA, SWEDEN.EXPECTED INCREASE IN DEMAND AND PRODUCTION CAPACITY OF VENTILATORS IS EXPECTED TO BE ACCRETIVE TO GETINGE'S RESULT.

Getinge Q4 Adjusted EBITDA Up At SEK 1.67 Bln

Jan 30 (Reuters) - Getinge AB <GETIb.ST>::GETINGE FULL YEAR REPORT 2019: CONTINUED GROWTH, HIGHER MARGINS AND STRENGTHENED CASH FLOW.Q4 NET SALES INCREASED BY 1.8% ORGANICALLY AND ORDER INTAKE ROSE BY 0.9% ORGANICALLY..Q4 ADJUSTED EBITA AMOUNTED TO SEK 1,673 M (1,412) AND ADJUSTED EBITA MARGIN WAS 19.7% (17.9).A DIVIDEND PER SHARE OF SEK 1.50 (1.00) IS PROPOSED, WHICH AMOUNTS TO SEK 409 M (272).OUR ORGANIC SALES GROWTH CONTINUED IN THE FOURTH QUARTER AND IT WAS PARTICULARLY GOOD TO SEE THE STRONG PERFORMANCE OF OUR THREE LARGEST MARKETS – THE US, CHINA AND GERMANY.WE IMPROVED THE MARGINS AND THE CASH FLOW BOTH IN THE QUARTER AND FOR THE FULL YEAR, AND THE BALANCE SHEET WAS STRENGTHENED.THE GROSS MARGIN FOR THE QUARTER WAS POSITIVELY IMPACTED BY A FAVORABLE SALES MIX, HIGHER PRODUCTIVITY AND CURRENCY EFFECTS..OUTLOOK 2020: ORGANIC SALES GROWTH IS EXPECTED TO BE 2-4% FOR THE FULL-YEAR 2020..REFINTIV POLL: GETINGE Q4 REVENUE SEEN AT SEK 8.49 BILLION, ADJUSTED. EBITDA AT SEK 2.07 BILLION, DIVIDEND AT SEK 1.72PER SHARE.GETINGE - Q4 NET SALES AT SEK 8.50 BILLION.

Getinge Acquires Applikon Biotech

Jan 8 (Reuters) - Getinge AB <GETIb.ST>::ACQUIRED 100% OF THE SHARES IN APPLIKON BIOTECHNOLOGY B.V..UNDER THE TERMS, GETINGE WILL ACQUIRE ALL OUTSTANDING SHARES IN APPLIKON BIOTECHNOLOGY AND WILL PAY APPROXIMATELY SEK 840 MILLION IN CASH ON CLOSING FOR 100 % OF THE SHARES.IN ADDITION, A MAXIMUM EARN OUT OF APPROXIMATELY SEK 630 MILLION CAN BE PAID OUT IN 2021-2022 IF AGREED EARNINGS PERFORMANCE IS ACHIEVED IN 2020-2021.ACQUISITION WILL BE FINANCED THROUGH DEBT AND THE NET DEBT TO EBITDA RATIO IS EXPECTED TO BE IMPACTED BY 0.2X AT CLOSING OF DEAL.THE INTEGRATION WILL BE STEPWISE WITH FULL EFFECT FROM 2022.GETINGE EXPECTS NO MATERIAL INTEGRATION COSTS IN 2020-2021.

Getinge To Acquire Applikon Biotechnology

Dec 19 (Reuters) - Getinge AB <GETIb.ST>::GETINGE TO ACQUIRE APPLIKON BIOTECHNOLOGY B.V., A LEADING COMPANY IN THE FAST GROWING AREA OF BIOREACTOR SYSTEMS.APPLIKON BIOTECHNOLOGY B.V. IS A COMPANY IN ADVANCED BIOREACTOR SYSTEMS FOR BIOPHARMACEUTICAL PRODUCTION AND RESEARCH,.GETINGE WILL ACQUIRE ALL OUTSTANDING SHARES IN APPLIKON BIOTECHNOLOGY B.V. AND WILL PAY APPROXIMATELY SEK 840 M (EUR 80 M).AGREEMENT TO ACQUIRE 100% OF SHARES IN APPLIKON BIOTECHNOLOGY B.V. FROM APPLIKON BIOTECHNOLOGY HOLDING B.V.MAXIMUM EARN OUT OF APPROXIMATELY SEK 630 M (EUR 60 M) CAN BE PAID OUT IN 2021-2022.ACQUISITION WILL BE FINANCED THROUGH DEBT.DEAL IS EXPECTED TO BE FINALIZED IN Q1 OF 2020.NET DEBT TO EBITDA RATIO IS EXPECTED TO BE IMPACTED BY 0.2X AT CLOSING OF DEAL IN Q1 OF 2020.INTEGRATION WILL BE STEPWISE WITH FULL EFFECT FROM 2022.EXPECTS NO MATERIAL INTEGRATION COSTS IN 2020-2021.EXPECTED TO HAVE A MATERIAL IMPACT ON OPERATING PROFIT AND EARNINGS PER SHARE AS OF 2020.

Getinge Announces Medical Device Recall/Field Action Related To Packaging Of QUADROX-iD Pediatric Oxygenators

Dec 18 (Reuters) - Getinge AB <GETIb.ST>::IS ANNOUNCING A MEDICAL DEVICE RECALL/FIELD ACTION RELATED TO PACKAGING OF QUADROX-ID PEDIATRIC OXYGENATORS.TO DATE THERE ARE NO KNOWN ADVERSE EVENTS ASSOCIATED WITH ILLNESS OR INJURIES RELATED TO DAMAGE TO STERILE BARRIER.COST FOR FIELD CORRECTION AND RECALL IS NOT MATERIAL.

Getinge announces voluntary recall of ROTAFLOW drive unit

Dec 4 (Reuters) - Getinge AB <GETIb.ST>::GETINGE SAYS IS ANNOUNCING A VOLUNTARY RECALL OF THE ROTAFLOW DRIVE UNIT.GETINGE SAYS TO DATE, THERE ARE NO KNOWN ADVERSE EVENTS ASSOCIATED WITH ILLNESS OR INJURIES RELATED TO THE DRIVE UNIT.GETINGE SAYS HAS REPORTED TO RELEVANT AUTHORITIES ACCORDING TO APPLICABLE REGULATIONS AND THE COST FOR THE FIELD CORRECTION AND RECALL IS NOT MATERIAL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up